A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression)

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2022
This article has no abstract
Epistemonikos ID: 6ff319b497339e4a41820b445fcabcf97bfbf46c
First added on: Apr 17, 2025